Another ADC, ADCT-701, which targets DLK1, a Notch ligand, linked to a PBD dimer, demonstrated efficacy in preclinical ACC xenografts, and a phase I trial is underway (Table 2).54,55 A third ADC, ADCT-211, which targets interleukin 13 receptor subunit alpha 2 (IL13RA2) linked to a PBD dimer, has shown antitumor activity in in vitro and in vivo studies, and a phase I trial is expected.56 This evidence concerns the gene IL13RA2 and adrenal cortex carcinoma.